CELL SIGNALING TECHNOLOGY, INC.
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 10 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 676 Total Citation Count
- Nov 13, 2001 Earliest Filing
- 59 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0031,559 METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPYOct 12, 17Feb 01, 18[G01N, C07K]
2018/0009,884 Production of Motif-Specific and Context-Independent Antibodies Using Peptide Libraries as AntigensAug 21, 17Jan 11, 18[C07K]
2015/0184,158 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMASep 11, 14Jul 02, 15[C12N]
2013/0059,305 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMASep 14, 12Mar 07, 13[C12Q, G01N]
2012/0308,555 METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIESMar 09, 12Dec 06, 12[A61K, C40B, C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9738711 Production of motif-specific and context-independent antibodies using peptide libraries as antigensDec 17, 14Aug 22, 17[C07K]
9587013 Immunoaffinity isolation of modified peptides from complex mixturesApr 23, 13Mar 07, 17[G01N, C07K, B01D]
9588110 Multi component antibody based detection technologyJul 27, 12Mar 07, 17[C12Q, C12N, G01N, C07K]
9523130 Methods of treating non-small cell lung carcinoma (NSCLC)Aug 02, 16Dec 20, 16[A61K, C12Q, C12N, G01N]
9453845 Mass spectroscopy analysis of mutant polypeptides in biological samplesFeb 01, 11Sep 27, 16[H01J, C12Q, G01N, B01D]
9328349 Translocation and mutant ROS kinase in human non-small cell lung carcinomaSep 11, 14May 03, 16[A61K, C12Q, C12N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0091,493 METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPYAbandonedDec 10, 15Mar 31, 16[G01N]
2014/0134,640 Gene Defects And Mutant ALK Kinase In Human Solid TumorsAbandonedJul 12, 13May 15, 14[G01N]
2013/0266,965 Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHAAbandonedFeb 28, 13Oct 10, 13[G01N]
2013/0209,452 GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORSAbandonedSep 14, 12Aug 15, 13[A61K, C12Q, G01N]
8446160 Probe card maintenance method which adjusts position/posture of probesExpiredFeb 01, 10May 21, 13[G01R]
2013/0071,841 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMAAbandonedOct 01, 12Mar 21, 13[C12Q, G01N]
2013/0059,304 TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMAAbandonedSep 14, 12Mar 07, 13[C12Q, G01N]
2012/0244,594 Immunoaffinity isolation of modified peptides from complex mixturesAbandonedJun 28, 07Sep 27, 12[H01J, C12S, C12N, G01N, C07K, B01D]
2012/0149,880 Nucleic Acid Cassette For Producing Recombinant AntibodiesAbandonedAug 20, 10Jun 14, 12[C12P, C12N, C07K]
2012/0101,108 Anaplastic Lymphoma Kinase In Kidney CancerAbandonedAug 05, 11Apr 26, 12[A61K, C12Q, G01N]
2011/0130,547 Reagents For The Detection Of Protein Phosphorylation In EGFR Signaling PathwaysAbandonedOct 04, 10Jun 02, 11[C07K]
2011/0104,820 Tyrosine, Serine, And Threonine Phosphorylation SitesAbandonedOct 12, 10May 05, 11[G01N, C07K]
2011/0105,732 Reagents for the Detection of Protein Phosphorylation in Carcinoma Signaling PathwaysAbandonedJan 06, 11May 05, 11[C07K]
2011/0045,534 Nucleic Acid Cassette For Producing Recombinant AntibodiesAbandonedNov 23, 09Feb 24, 11[C07H, C12P, C12N, C07K]
2011/0045,603 Serine, Threonine, and Tyrosine Phosphorylation SitesAbandonedApr 20, 10Feb 24, 11[G01N, C07K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
